Library
PubMed
research article
Professional

The Present and Future of THERANOSTICS.

Source: PubMed, NCBI / U.S. National Library of Medicine

Asia-Pacific journal of clinical oncologyLam Winnie Wing-Chuen, Thang Sue Ping, Loke Kelvin Siu-Hoong, et al.Published 6/2/2026Last synced 6/3/2026Status: syncedPMID: 42231053DOI: 10.1111/ajco.70126

There is a growing worldwide interest in the detection and targeted treatment of cancer with radiotheranostics as part of precision medicine. This article reviews some of the developments in theranostics, namely, approved radiopharmaceuticals, agents in late-stage clinical trials, emerging radionuclides and targets, as well as operational and regulatory challenges. Other areas of development include use of novel ligands, new indications, and combinations with other systemic therapies. We aim to provide an overview of radiopharmaceutical therapies in use and in clinical development and consider some of the challenges in East and Southeast Asia, including an innovative yet highly regulated environment in Singapore.

Educational only
This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.